LJPC-501

FDA Agrees that La Jolla Pharmaceutical Has Sufficient Data for Investigational New Drug Application
San Diego Business Journal, CA
Wed, 03/6/13 - 10:56 am
La Jolla Pharmaceutical
LJPC-501
hepatorenal syndrome